Nasdaq: CBIO

CATALYST

BIOSCIENCES

Corporate Overview

28 September 2021

CatalystBiosciences.com

Forward looking statements

Certain information contained in this presentation and statements made orally during this presentation include forward-looking statements that involve substantial risks and uncertainties. All statements included in this presentation, other than statements of historical facts, are forward-

looking statements. Forward-looking statements include, without limitation, statements about the product candidates of Catalyst Biosciences, Inc. (the "Company") and the benefits of its protease engineering platform, potential commercial opportunities for and advantages of MarzAA and DalcA, including their potential to treat hemophilia subcutaneously; plans to enroll the Crimson 1 Phase 3 registration study and report on actions of the DSMB and treatment of bleed data for this study; plans to enroll the MAA Phase 1/2 study of MarzAA and report PK and treatment of bleed data for this study; the potential markets for and advantages of the Company's complement​ product candidates, including CB 2782PEG- as a potential best-in-class C3 degrader for dry AMD, CB 4332 as a potential treatment for CFI deficiency, and complement degraders; plans for the Company's collaboration with Biogen; potential markets for the Company's CFI complement product candidates, and plans to enroll the CB 4332 observational trial and to conduct human clinical trials for CB 4332.​

Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements.

Various important factors could cause actual results or events to differ materially, including, but not limited to, the risk that trials, studies or programs may be delayed or terminated as a result of COVID-19 and other factors, that trials may not have satisfactory outcomes, that human trials will not replicate the results from earlier trials, that the Company will need to raise additional capital, which may not be available on favorable terms, if at all, the risk that costs required to develop or manufacture the Company's products will be higher than anticipated, including as a result of delays in development and manufacturing resulting from COVID-19 and other factors, the risk that Biogen will terminate its agreement with the Company, competition and other risks described in the "Risk Factors" section of the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 4, 2021, on Form 10-Q filed with the SEC on August 5, 2021, and in other filings with the SEC. The forward-looking statements in this presentation represent the Company's view as of the date of this presentation and the Company does not assume any obligation to update any forward-looking statements, except as required by law.

© Catalyst Biosciences

2

The Protease Medicines Company

Harnessing the catalytic power of proteases

Novel differentiated medicines

Robust complement portfolio

Clinical-stage assets

Unique expertise in protease engineering

© Catalyst Biosciences

3

Catalyst protease platform

Unique expertise enables design of optimized & differentiated protease candidates

Discovery Platform

Protease

Protease

Scaffold

Candidate

Structure Guided Design

Engineered Regulation

Molecular Evolution

Pharmacokinetic Improvement

© Catalyst Biosciences

Our Proteases

  • Functionally enhanced natural proteases in the complement & coagulation cascades
  • Engineered novel protein degraders in the complement cascade
  • Modulate or target biological activation or inactivation

4

Proteases are ideal for high abundancy targets & cascades

A better way to regulate biological processes compared with antibodies & small molecules

Protease

Therapeutic target neutralization

Efficient regulation at low concentrations of therapeutic protease

Antibodies

Requires high concentrations in excess of the target

Small molecules /

peptides

Requires high concentrations & frequent dosing

© Catalyst Biosciences

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Catalyst Biosciences Inc. published this content on 28 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 September 2021 17:41:05 UTC.